Update on the Use of Vonoprazan: A Competitive Acid Blocker

被引：87
作者：
Graham, David Y. [1 ,2 ]
Dore, Maria Pina [3 ]
机构：
[1] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Univ Sassari, Sassari, Italy
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 03期
关键词：
RANDOMIZED CLINICAL-TRIAL; HELICOBACTER-PYLORI ERADICATION; PROTON PUMP INHIBITORS; VS; LANSOPRAZOLE; TRIPLE THERAPY; PHARMACOKINETICS; HYPERGASTRINEMIA; METAANALYSIS; RESISTANCE; COMPONENT;
D O I：
10.1053/j.gastro.2018.01.018
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：462 / 466
页数：5
相关论文
共 32 条
[1]   Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - Update 2004 [J].
Armstrong, D ;
Marshall, JK ;
Chiba, N ;
Enns, R ;
Fallone, CA ;
Fass, R ;
Hollingworth, R ;
Hunt, RH ;
Kahrilas, PJ ;
Mayrand, S ;
Moayyedi, P ;
Paterson, WG ;
Sadowski, D ;
van Zanten, SJV .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 (01) :15-35
[2]   Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis [J].
Ashida, K. ;
Sakurai, Y. ;
Hori, T. ;
Kudou, K. ;
Nishimura, A. ;
Hiramatsu, N. ;
Umegaki, E. ;
Iwakiri, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) :240-251
[3]   Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis [J].
Ashida, K. ;
Sakurai, Y. ;
Nishimura, A. ;
Kudou, K. ;
Hiramatsu, N. ;
Umegaki, E. ;
Iwakiri, K. ;
Chiba, T. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (06) :685-695
[4]   ACG Clinical Guideline: Treatment of Helicobacter pylori Infection [J].
Chey, William D. ;
Leontiadis, Grigorios I. ;
Howden, Colin W. ;
Moss, Steven F. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (02) :212-239
[5]   Helicobacter pylori infection and antibiotic resistance: a WHO high priority? [J].
Dang, Bich N. ;
Graham, David Y. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (07) :383-384
[6]   Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? [J].
Dong, Shou Quan ;
Singh, Tikka Prabhjot ;
Wei, Xin ;
Yao, Huang ;
Wang, Hong Ling .
HELICOBACTER, 2017, 22 (06)
[7]   Role of bismuth in improving Helicobacter pylori eradication with triple therapy [J].
Dore, Maria Pina ;
Lu, Hong ;
Graham, David Y. .
GUT, 2016, 65 (05) :870-878
[8]   The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations [J].
Echizen, Hirotoshi .
CLINICAL PHARMACOKINETICS, 2016, 55 (04) :409-418
[9]  
FAHRENKRUG J, 1976, GASTROENTEROLOGY, V71, P33
[10]   Proton pump inhibitors - Do differences in pharmacokinetics translate into differences in clinical outcomes? [J].
Fock, Kwong Ming ;
Ang, Tiing Leong ;
Bee, Lean Choo ;
Lee, Edmund Jon Deon .
CLINICAL PHARMACOKINETICS, 2008, 47 (01) :1-6
1234